The global dipeptidyl peptidase-4 (DPP-4) inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are expected to boost the market growth include increasing incidences of diabetes, particularly type-2 diabetes, as well as an increase in obesity populations. Moreover, an increase in clinical trials on the DPP-4 drugs is another factor that is expected to accelerate the growth of the market during the forecast period. The prevalence of diabetes in 2019 across the globe was more than 463 million and is projected to increase during the forecast period as per the International Diabetes Federation (IDF). The dipeptidyl peptidase 4 (DPP-4) inhibitors support in the release of insulin secretion in the patients' body and regulate the sugar levels in the body. Hence, such factors are likely to enhance the growth of the market during the forecast period. However, numerous side effects associated with the intake of dipeptidyl peptidase 4 (DPP-4) inhibitors is restraining the growth of the market.

Tradjenta includes its combination Jentadueto and Jentadueto XR, a combination of linagliptin (Tradjenta) and metformin hydrochloride, for use in the treatment of type 2 diabetes. The type-2 diabetes drug, Tradjenta (linagliptin) was not launched in Germany due to the decision by the county’s reimbursement authority, which concluded that it doesn’t provide any additional benefits, compared to the medicines already on the market. In order to maintain a strong position in the market, these market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. Merck held the highest market share in the DPP-4 inhibitors market and is expected to maintain its position till 2022. After that, it may witness a decline in market share, due to the expected launch of a generic version of Sitagliptin in 2022.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Drug

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape: Merck and Co., Inc., AstraZeneca plc, Eli Lilly and Co., and Boehringer Ingelheim GmbH, among others. 

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How are players addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market Report by Segment

By Drug

    • Januvia

    • Onglyza/Kombiglyze

    • Tradjenta

    • Nesina

    • Galvus

    • Others

Global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market Report by Region

North America       

    • US

    • Canada

Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe

Asia-Pacific    

    • China

    • Japan

    • India

    • Rest of Asia-Pacific

Rest of the World

    • Latin America

    • Middle East and Africa